title: [FREQUENCY OF POLYMORPHISM OF VKORC1 AND CYP2C9 GENES IN TWO REGIONS OF GEORGIA].
abstract: The aim of the research was to study the frequency of VKROC1 and CYP2C9 genes different alleles for healthy donors and for patients with thrombosis, in two regions of Georgia - in Samegrelo and in Tbilisi and to reveal the interdependence of the studied genes products in the treatment of thrombosis with warfarin. Warfarin is an anticoagulant, causing the inactivation of the VKORC1 gene product, which is one of the clotting factors. The protein product of CYP2C9 gene is involved in the metabolism of warfarin. Genotyping of blood samples for studied genes alleles was carried out using a tube scanner (ESE Quant Tube Scaner), allowing to identify SNPs. In the studied group of patients with thrombosis from Samegrelo region the wild-type homozygotes by the gene VKORC1 were - 90%; heterozygotes - 10%; mutant homozygotes have not met at all. In the studied group of patients with thrombosis from Tbilisi, also predominated homozygous wild type (60%); heterozygotes were - 40%; mutant homozygotes were not met. The genotypes of healthy donors fromTbilisi does not differed from the same indicator of of Samegrelo (homozygous "wild" AA - 37%; genotype AB - 47%; and mutant genotype - BB - 16%). In patients with thrombosis, from Samegrelo, wild-tipe homozygotes and heterozygotes by CYP2C9 gene were almost the same rate (51% and 49% -, respectively); mutant homozygotes were not revealed. In patients from Tbilisi, the frequency of wild-type homozygotes was 70%, heterozygotes and mutant homozygotes was 20% and 10% - respectively. The ratio of the frequencies of CYP2C9 gene alleles in healthy donors from Tbilisi and Samegrelo is not different - wild-type homozygotes - 77%; heterozygotes - 23%; mutant homozygotes in both regions were not met. VKORC1 and / or CYP2C9 genes polymorphisms are presented in a number of clinical dosing algorithms and in prospective clinical trials. It is revealed the significant variation of genotypes in patients with thrombosis (in both studied regions), which indicates the importance of as in treatment process, as well as for the prevention of thrombosis.
authors: Iv. Javakhishvili Tbilisi State University; Tbilisi State Medical University, Georgia.
authors: T
authors: T
authors: Jokhadze
authors: Iv. Javakhishvili Tbilisi State University; Tbilisi State Medical University, Georgia.
authors: N
authors: N
authors: Kakauridze
authors: Iv. Javakhishvili Tbilisi State University; Tbilisi State Medical University, Georgia.
authors: T
authors: T
authors: Buadze
authors: Iv. Javakhishvili Tbilisi State University; Tbilisi State Medical University, Georgia.
authors: M
authors: M
authors: Gaiozishvili
authors: Iv. Javakhishvili Tbilisi State University; Tbilisi State Medical University, Georgia.
authors: T
authors: T
authors: Lezhava
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D016022:Case-Control Studies; D065729:Cytochrome P-450 CYP2C9 / Q000235:genetics*; D005787:Gene Frequency; D005838:Genotype; D005846:Georgia (Republic); D006801:Humans; D009154:Mutation; D011110:Polymorphism, Genetic; D013927:Thrombosis / Q000235:genetics* / Q000517:prevention & control; D064417:Vitamin K Epoxide Reductases / Q000235:genetics*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D065729:Cytochrome P-450 CYP2C9; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases